Eisai has reported positive results from analysis of the subpopulation of subjects in the Greater China region participating in its Phase III REFLECT clinical trial of lenvatinib mesylate (Lenvima) to treat unresectable hepatocellular carcinoma (HCC).

Discovered and developed by the firm, lenvatinib is an oral inhibitor of multiple receptor tyrosine kinase (RTK) being developed to selectively inhibit the kinase activities of vascular endothelial growth factor (VEGF) receptors and fibroblast growth factor (FGF) receptors.

Based on an extension of overall survival (OS) in the subpopulation, lenvatinib was found to be effective when compared with sorafenib as a first-line treatment in the REFLECT trial.

The drug candidate further demonstrated improvements in progression-free survival (PFS), time to progression (TTP) and objective response rate (ORR).

REFLECT’s Greater China subpopulation included 288 patients out of the total 954 subjects participating in the trial.

“The drug candidate further demonstrated improvements in progression-free survival, time to progression and objective response rate.”

It was observed that for 80% of these patients whose HCC was due to chronic hepatitis B virus infection, their median OS using lenvatinib was 14.9 months compared with 9.9 months with sorafenib.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results indicated that the safety profile for the subpopulation was consistent with that of its previous studies.

Lenvatinib is currently approved for the treatment of refractory thyroid cancer in more than 50 countries such as the US and Japan, in addition to Europe.

As a combination therapy with everolimus, the drug candidate is approved as a second-line treatment for renal cell carcinoma various countries.

The firm is also conducting a Phase Ib trial with lenvatinib for HCC, along with a Phase Ib/II trial with pembrolizumab combination for certain solid tumours.